Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Sentinel Transition Will Involve Expanding Rx Safety Data Sources

Executive Summary

Moving Mini-Sentinel pilot program to a fully operational and sustainable Sentinel postmarket safety surveillance system will take place over next year, CDER Director Woodcock says.

You may also be interested in...



FDA’s Sentinel Likely To Outpace Traditional Post-Market Studies, But Will It Replace Them?

Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.

Bridge Too Far? BMS Launch Plan For Sotyktu Pressured By Prospect Of Medicare Price Controls

With price controls in Medicare looming nine years after approval, launch strategies such as ‘bridge’ programs that build initial volume with free drug may have to be adjusted.

Medicare Wastage Rebate Exceptions For Small Volume Products, Cell/Gene Therapy Urged

Packaging for such products reflects ‘unique circumstances’ that should exempt them from the rebates on discarded drugs otherwise required by the policy, stakeholders tell CMS at a ‘town hall’ forum.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS056667

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel